Stocks › AMRX
Amneal Pharmaceuticals Inc (AMRX) stock analysis
WEAK BUY 25% confidence · analysed Sep 30, 2026
On Sep 30, 2026, our model rated Amneal Pharmaceuticals Inc (AMRX) WEAK BUY with 25% confidence at a price of $20.20. That means the signals lean positive, but they are mixed, so conviction is low.
Technical picture
The 14-day RSI is 71, above 70, which is overbought: buyers have been very aggressive and a pause or pullback is common from here.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is about normal (1.1x the 20-day average).
Trend structure and money flow
Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $15.42 and the swing low is $11.71; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 1.92, which looks reasonably priced for its growth.
The company reports a profit margin of 5.0% and revenue growth of +9.9%.
In its latest quarter it earned $0.30 per share, which beat the $0.23 analysts expected, with revenue +9.9% year over year.
Wall Street's average rating is 1.4 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $22.71.
The next earnings report is expected around Oct 29, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $20.23, a target of $22.00 (+8.7%) and a stop-loss at $18.29 (-9.6%).
That is a reward-to-risk ratio of about 0.9 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Oct 10, 2026 whatever the price does.
The model's one-paragraph read
Leans BUY — composite score +0.25 (WEAK BUY). Technicals: RSI 70.54, MACD bullish, price above SMA50. Fundamentals: PEG 1.92, margin 5.0%, revenue growth 9.9%. Financial results: YoY revenue +9.9%, last EPS surprise +30.4%, next earnings 2026-10-29. Smart Money Concepts: BOS bullish (trend continuation). FinGPT news read: positive. Memory: 23 prior look(s); 92% of directional calls matched later price. Suggested levels: entry $20.23, target $22.0, stop-loss $18.29, exit by 2026-10-10 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for AMRX
Of the last 9 directional calls on AMRX, 8 pointed the right way by the most recent analysis (89%). Past calls do not guarantee future results.
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Sep 30, 2026 | WEAK BUY | 25% | $20.20 | — | |
| Sep 29, 2026 | WEAK BUY | 24% | $20.50 | -1.5% | ✘ wrong direction |
| Sep 28, 2026 | WEAK BUY | 24% | $19.92 | +1.4% | ✔ right direction |
| Sep 24, 2026 | WEAK BUY | 26% | $19.33 | +4.5% | ✔ right direction |
| Sep 23, 2026 | WEAK BUY | 26% | $19.14 | +5.5% | ✔ right direction |
| Sep 18, 2026 | WEAK BUY | 31% | $18.35 | +10.1% | ✔ right direction |
| Sep 17, 2026 | WEAK BUY | 32% | $18.24 | +10.7% | ✔ right direction |
| Sep 16, 2026 | WEAK BUY | 12% | $17.17 | +17.6% | ✔ right direction |
| Sep 15, 2026 | SKIP | 10% | $16.92 | +19.4% | |
| Sep 14, 2026 | WEAK BUY | 17% | $17.06 | +18.4% | ✔ right direction |
| Sep 10, 2026 | SKIP | 12% | $17.25 | +17.1% | |
| Sep 9, 2026 | WEAK BUY | 23% | $17.05 | +18.5% | ✔ right direction |
"Move since" compares each call's price with the latest analysed price.
Other Healthcare stocks we cover
ANIP · ASTH · ATEC · ATRC · BCRX · BDX · BIIB · BMY · BSX · CNC · COO · CVS
Frequently asked questions
Is AMRX a buy right now?
As of Sep 30, 2026, our automated model rates Amneal Pharmaceuticals Inc (AMRX) WEAK BUY with 25% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for AMRX?
The model's most recent plan targets $22.00 with a stop-loss at $18.29, from an entry near $20.23.
When does Amneal Pharmaceuticals Inc report earnings next?
The next earnings report is expected around Oct 29, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.